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Background: The presence of anxiety and depressive symptoms in COPD patients has been acknowledged for
many years. The preponderance of recent studies supports the utility of pulmonary rehabilitation programs to
reduce the levels of depression and anxiety in these patients. The aim of this study is to investigate possible
changes in levels of anxiety and depression among patients enrolled in a pulmonary rehabilitation program, along
with the role of disease severity in these changes.
Methods: In 101 COPD patients, who attended a pulmonary rehabilitation program, levels of trait anxiety (STAI)
and depressive symptoms (BDI) were assessed at the beginning and at the end of the program. Age, sex, level of
education in years and stage of disease severity were recorded.
Results: Our study included 80 male and 21 female patients. Mean age and mean education level were 64.1 ± 8.1
and 11.3 ± 4.1 years, respectively. Regarding COPD staging, 11 patients suffered from mild, 16 from moderate, 47
from severe and 27 from very severe COPD. Significant decreases in anxiety (from 39.7 to 34.0, p < 0.001) and
depression rates (from 10.7 to 6.3, p < 0.001) were observed. A statistically significant reduction in anxiety and
depression was revealed (p < 0.05)at all stages of COPD.
Conclusion: Pulmonary rehabilitation programs should be offered to all COPD patients irrespective of disease
severity, since they all lead to improvement in anxiety and depressive symptoms.
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Over the last decades, therapeutic evolution in
healthcare,in conjunction with an increase in average life
expectancy, resulted in a significant and gradual dimin-
ution in medical emergencies but simultaneously gave
rise to chronic progressive and debilitating diseases.
Gradual reintegration of the chronically suffering pa-
tients in family, social and professional environment is
nowadays a challenge for the therapeutic team. Social in-
tegration is continuously threatened by a constellation of
factors concerning the nature of the disease and by the
psychosocial parameters implicating the dynamic task of* Correspondence: atselebis@yahoo.gr
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reproduction in any medium, provided the oradjustment mechanisms that constitute the subjective
experience of the illness.
It is well known that Chronic Obstructive Pulmonary Dis-
ease (COPD) is a disease with psychological comorbidities.
Several studies have suggested that the prevalence of
anxiety and depression among patients with COPD is
substantially greater than lifetime rates in the general
population and higher than in patients with other pul-
monary diseases such as bronchial asthma and tuber-
culosis [1], or other chronic diseases such as chronic
heart failure [2]. International prevalence rates of clin-
ical depression in COPD patients rise above 30% and
sometimes above 50% [3], whereas corresponding rates
in the background population is around 6-8% [4].
Studies in Greece also report high prevalence rates of
depression in COPD patients, often above 42% [1].
Moreover, studies indicate rates of anxiety varyingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lence rate of 15% mentioned in the general population
[5]. Additionally, one out of two patients with COPD
disease appears to suffer from general psychopatho-
logical symptoms [6].
Recent studies show a reduction in anxiety and de-
pression symptoms among patients with COPD that are
enrolled in pulmonary rehabilitation programs [7-9];
nevertheless some authors believe that further studies
are needed [10]. Several studies have pointed out that
the degree of psychological improvement brought about
by the program depends on disease severity stage. These
studies mostly deal with severe COPD (usually leaving
out stage I disease) [11,12].
The aim of this study is to investigate the change in
anxiety and depressive symptoms among patients with
COPD disease who attended a pulmonary rehabilitation
program, along with the effect of disease severity on this
change. Specifically, we assessed whether the rehabilita-
tion program alters anxiety and depression in patients




The study lasted four years and involved all patients with
COPD who attended a pulmonary rehabilitation pro-
gram and met the criteria for inclusion in the study. All
interested patients with COPD (for whom there was no
contraindication such as angina pectoris, myocardial in-
farction, severe pulmonary hypertension, congestive
heart failure, labile diabetes, inability to exercise due to
orthopedic or other reasons, dementia or severe hypoxia
caused by exercise and corrected by O2 administration)
were admitted to this rehabilitation program [13]. The
sample consisted of 101 COPD patients, 80 males and
21 females, who completed a three months program. In-
clusion criteria were the following: age less than 80 years,
without other chronic comorbid medical conditions (car-
diovascular diseases, major psychiatric disorders, etc.)
and absence of acute exacerbation of COPD during the
last two months before starting the program. We ex-
cluded patients who did not meet the inclusion criteria
(n = 12) as well as those who did not complete the re-
habilitation program (n = 43).
Physical measures
In order to determine COPD severity of our sample, a
spirometric evaluation before and after bronchodilation
(200 μg salbutamol) was performed. We followed the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) diagnostic criteria, which classifies COPD
severity [in relation to forced expiratory volume in 1 sec-
ond (FEV1)/forced vital capacity (FVC) ratio (FEV1%) -percentage of predicted] into four stages: stage I (mild
COPD): FEV1 > 80% predicted; stage II (moderate
COPD): FEV1 50% to 80% of predicted; stage III (se-
vere COPD): FEV1 30% to 50% of predicted; and stage
IV (very severe COPD): FEV1 < 30% of predicted [14].
The spirometric evaluation of each patient was
performed a few days before he/she started the re-
habilitation program.
Psychological measures
Depression was assessed with the Beck Depression In-
ventory (BDI) [15], which is widely used, and has been
standardized [16] and used in the Greek population pre-
viously [17]. The BDI includes 21 items graded from 0
to 3. The inner coherence reliability is high and the re-
test reliability ranges from 0.48 to 0.86 for clinical
groups and 0.60 to 0.90 for non-clinical population.
Its validity in relation to an external criterion for
depression, such as clinical diagnosis, is considered to be
satisfactory. Anxiety was assessed with the Spielberger
State-Trait Anxiety Inventory (SSTAI) [18], one of the
well-known and broadly used anxiety rating scales. The
inventory consists of 40 items, each one graded from
1 to 4. The SSTAI differentiates anxiety to (a) anxiety
caused by a specific condition (state subscale), and (b)
anxiety as a more permanent characteristic of the per-
sonality (trait subscale). This second (trait) subscale was
used in our study protocol. The SSTAI is considered as
having a high inner coherence reliability and validity
compared to clinical diagnosis. Also it has been stan-
dardized [19] and widely used in studies in the Greek
population previously [20]. Participants replied to
the questionnaires in two phases, at baseline and at
discharge from the pulmonary rehabilitation program.
Pulmonary rehabilitation program
Patients of our study followed a pulmonary rehabilita-
tion program for a period of three months, with three
sessions per week, each lasting 50 minutes. The program
included respiratory physiotherapy, respiratory muscle
training, aerobic exercise on a bicycle ergometer and on
a treadmill and strengthening of muscle groups. The exer-
cise was performed with oxygen supplementation while
simultaneously recording heart rate and hemoglobin sat-
uration. The minimum and maximum number of sessions
per patient was 34 and 39, respectively, with an average of
37 per patient.
Statistical analysis
The statistical program used was SPSS 16. The statistical
analysis was performed using x2 test, paired t-test,
ANOVA, sample t-test, Pearson correlation and stepwise
multiple regression. For regression models, an empirical
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significance was set at p < 0.05.
The hospital ethics committee approved the study and
all participants provided written informed consent. No
financial support was necessary.
Results
Sample characteristics
The demographic characteristics of our patients and
their spirometric values are summarized in Table 1.
There were no differences between genders regarding
age, years of education and FEV1 percentage of predicted
(t-test p > 0.05). With regard to the severity of COPD
according to GOLD classification, the number of pa-
tients with severe COPD disease (47 patients, 46.5% of
the total sample) was significantly higher than that of
other subgroups (x2 p < 0.01, Table 1).
Changes in anxiety and depression
Mean depression and anxiety scores were significantly
lower at discharge compared to baseline for all our pa-
tients (paired t-test p < 0.05, Table 2). Same findings
were revealed for all subgroups (according to staging of
COPD disease) of patients and no statistical difference
was identified when checking for mean individual
changes in depression and anxiety scores among all dif-
ferent disease severity subgroups (ANOVA p > 0.05).
Mean BDI score, at baseline, for the total of our
sample was 10.7, which is significantly (sample t-test
p < 0.05) higher than the corresponding mean score
(5.86) [16] in the general population. At discharge from
the program, mean BDI score was 6.33, not statistically
different from the corresponding mean score in the gen-
eral population (sample t-test p > 0.05). The rate of pa-
tients who had depressive symptoms (BDI > 9) [16] at
baseline was 47.5% (48 patients, Table 3) whereas atTable 1 Demographics and baseline characteristics
Age Education level
(years)
Male Mean 64.56 10.90
N 80 80
SD 8.06 4.09
Female Mean 62.57 12.67
N 21 21
SD 8.38 3.75
Total Mean 64.15 11.27
N 101 101
SD 8.13 4.07
Severity according to Global Initiative for Chronic Obstructive Lung Disease (
mild/moderate/severe/very severe: 11 (10.9%)/16 (15.8%)/47 (46.5%)/27 (26.7%
BDI Beck depression inventory, STAI Spielberger trait anxiety inventory.discharge it became 14.9% (15 patients, Table 3), which
was a statistically significant reduction (x2 p <0.05).Changes in anxiety and depression per gender
Regarding anxiety scores our observations indicated that
mean scores at baseline were higher than the corre-
sponding scores in the general population. Specifically,
female patients of our sample had a mean STAI score of
42.62 (versus 37.47 [19] in the general female popula-
tion, sample t-test p < 0.01), while men had an average of
38.87 (versus 34.54 [19] in the general male population,
sample t -test p <0.01). At discharge our study indicated
reduced mean STAI scores for both female (36.29) and
male patients (33.4). These scores were not statistically
different from the corresponding mean scores in the
general population (sample t-test p > 0.05). The rate of
female patients who had clinically significant anxiety
symptoms (STAI > 45) at baseline was 47.6% and was re-
duced to 19% at discharge (x2 p < 0.05). Regarding male
patients of our sample, 25% of them had clinically
significant anxiety symptoms (STAI > 43) at baseline
and the percentage was reduced to 12.5% at discharge
(x2 p < 0.05).Correlations
A significant positive correlation was observed between
anxiety and depression scores both at baseline and
at discharge from the program (Pearson correlation
p < 0.01, Table 4).
A significant positive correlation was also observed be-
tween first and last measuring for both anxiety and de-
pression (Pearson correlation p < 0.01, Table 3), but no
correlation was found between FEV1% of predicted
and anxiety – depression scores (Pearson correlation
p > 0.05, Table 4).FEV1 Depression Anxiety












Table 2 Means (SD) and differences in BDI and STAI at baseline and after PRP in COPD severity subgroups
COPD Severity
(as per GOLD)
Time 1 Time 2 Difference
Depression Anxiety Depression Anxiety Depression Anxiety
(BDI) (STAI) (BDI) (STAI) (BDI) (STAI)
mild Mean 12.27 43.18 8.36 39.27 −3.91* −3.91*
N = 11 SD 5.55 8.15 7.21 9.88 5.24 5.86
moderate Mean 8.44 38.75 4.06 30.62 −4.37* −8.12**
N = 16 SD 5.66 8.34 2.67 7.59 6.91 8,20
severe Mean 11.43 39.62 6.85 33.96 −4.57** −5.66**
N = 47 SD 7.58 10.59 6.04 9.34 5.73 8.08
very severe Mean 10.15 38.81 5.93 33.93 −4.22** −4.89**
N = 27 SD 4.75 8.71 5.48 8.39 4.77 5.65
Total Mean 10.70 39.65 6.33 34.00 −4.38** −5.65**
N = 101 SD 6.45 9.49 5.69 9.04 5.56 7.30
* Paired t-test p < 0.05.
**Paired t-test p < 0.01.
BDI Beck depression inventory, STAI Spielberger trait anxiety inventory.
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regression analysis using variation in depression as the
dependent variable and controlling for gender, age,
FEV1%, years of education and variation in anxiety (inde-
pendent variables). Gender, age, years of education
and FEV1% were not involved in the variance of
the dependent variable whereas variation in anxiety
interpreted 34.3% of variation in depression (f 1.97 =
50.62, p <0.01). Considering anxiety variation as the
dependent variable and gender, age, years of education,
FEV1% as independent variables the results were not dif-
ferent, since variation in anxiety scores was independent
of gender, age and FEV1%, whereas variation in depres-
sion interpreted 34.3% of variation in anxiety (f 1.97 =
50.62, p <0. 01).
Discussion
Summarizing the results of this study, we have shown
that a rehabilitation program can reduce the high levels
of anxiety and depression in patients with COPD. Im-
provement occurs for patients in all disease stages (with
no statistically significant differences among them),Table 3 Severity of COPD and depressive symptoms severity
BDI: 0-9
time one time two time
COPD Severity (GOLD criteria) Mild 3 9 7
Moderate 11 16 4
Severe 24 36 17
Very severe 15 25 10
Total 53 86 38irrespective of gender. This improvement is not
dependent on disease stage, gender, age or years of edu-
cation. Spirometry showed no correlation with either
anxiety or depression in the course of the program and
anxiety and depression were not correlated with the se-
verity of COPD”.
Despite the high prevalence and harmful effects attrib-
uted to the comorbidity of anxiety and depression in
COPD, only a limited number of studies have addressed
their management [21,22].
Drug treatment encounters serious problems. Benzodi-
azepines may cause respiratory depression and should be
avoided [23]. In addition, beta-blockers are contraindi-
cated in these patients, despite their anxiolytic action,
because of the potential risk of bronchoconstriction [24].
Atypical antipsychotics in very small doses can alleviate
anxiety symptoms in these patients, but they should be
used cautiously because of possible neurological and car-
diovascular side effects [25]. In other studies SSRIs have
been used (first-line drugs for the management of de-
pression) [26-30]. Sertraline [28,29], fluoxetine [26,31]
citalopram [32] and paroxetine [30] may improve qualityDepressive symptoms severity Total
BDI:10-18 BDI:19-29 BDI > 29
one time two time one time two time one time two
1 1 1 0 0 11
0 1 0 0 0 16
9 5 1 1 1 47
1 2 1 0 0 27
11 9 3 1 1 101
Table 4 Correlations
N = 101 AGE Education (years) FEV1% BDI 1 BDI 2 STAI 1
Education level (in years) Pearsons’ r -.063
Sig. (2-tailed) .532
FEV1% Pearsons’ r .095 .014
Sig. (2-tailed) .349 .893
Depression (BDI 1) Time 1 Pearsons’ r -.076 -.056 .010
Sig. (2-tailed) .447 .575 .923
Depression (BDI 2) Time 2 Pearsons’ r -.091 .097 .053 .586**
Sig. (2-tailed) .365 .337 .601 .000
Anxiety (STAI 1) Time 1 Pearsons’ r -.223* -.056 .034 .726** .408**
Sig. (2-tailed) .025 .575 .741 .000 .000
Anxiety (STAI 2) Time 2 Pearsons’ r -.194 .131 .041 .610** .717** .691**
Sig. (2-tailed) .052 .190 .688 .000 .000 .000
* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed).
BDI Beck depression inventory, STAI, Spielberger trait anxiety inventory.
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psychiatric comorbidity are reluctant to take additional
medications [26,33].
Both individual and group therapy are useful for the
treatment of patients with COPD [34]. The comparison
of individual and group intervention usually favors the
latter [35-41]. Group therapy is a financially attractive
treatment approach that requires few therapists to treat
more patients. Furthermore it seems that group therapy
offers valuable treatment opportunities, which may be
due to recognition of shared experiences and emotions
among its members in a situation resembling the real
world more accurately [39].
It is very likely that improvement of psychological
symptoms in rehabilitation programs is associated with
both psychological, and biological parameters (which are
closely coupled with the effects of exercise and respira-
tory physiotherapy).
Biological mechanisms associated with exercise activ-
ity, including changes in central monoamine function
[36-40], enhanced hypothalamic- pituitary- adrenal axis
regulation, increased release of endogenous opioids
[42-49] and reduced systemic inflammation [49,50], may
affect depression and anxiety among patients undergoing
PR. In addition, behavioral mechanisms [51-56] associ-
ated with exercise activity as active distraction from
worrying thought patterns (rumination), increase in self-
efficacy by providing patients with a meaningful mastery
experience, provision of daily pleasant events and regular
social contact and support, operate synergistically to
produce reductions of symptoms.
The fact that patients participate in a pulmonary re-
habilitation program, which, with the necessary modifi-
cations, works in a way that refers to the functioning ofgroups formed by people sharing common characteris-
tics [39], acts therapeutically. Moreover, it is well
knownthat the sense of belonging to a group is often
beneficial, as it provides the opportunity for participants
to trigger interactions and through this process to iden-
tify elements of personal experience among others, and
to process them in a healthier way [57].
The results of this study are consistent with reports of
strong evidence of psychological/psychiatric benefits of
pulmonary rehabilitation [58-61], (such as improved
mood and anxiety) in patients with COPD [62,63]. This
study is in accordance with previous findings indicating
that patients with less favorable psychological conditions
may also benefit from a rehabilitation program [64].
An additional finding is that the effectiveness of a pul-
monary rehabilitation program in reducing stress and
depressive symptoms experienced by patients with
COPD, is undeniable, regardless of disease stage, pa-
tients’ gender, age or education level.
Furthermore, this study is in agreement with findings
of other related works [29,30] that reported anxiety and
depression as being the major comorbidity problem in
patients with COPD. However, the prevalence of comor-
bidity seems to vary widely among different researchers
[25,65-67]. The acceptance of common assessment tools
for stress and depression in patients with COPD could
mitigate the problem.
Finally, the positive correlation between anxiety and
depression is a common finding in both the general
population [5,20] and in patients with COPD [1,6,68].
The fact that the predicted FEV1% and severity of
COPD showed no correlation with anxiety or depression
has been observed in other studies [6,68]. These obser-
vations are consistent with the hypothesis that the
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ease [69]. It is likely that patients interpret disease
seriousness subjectively, which contributes to the
development of the levels of anxiety and depressive
symptoms.
Limitations of the study
The purpose of this study was to assess whether a
brief three month rehabilitation program can improve
levels of anxiety and depression in patients with
COPD without being able to answerbut only to specu-
late on the reasons for this improvement. Subsequent
studies should focus on exploring the causes of the
improvement.
This was a short-term before-and-after design study
(which is most useful in delineating immediate effects of
short-term programs). Although it might be more useful
in COPD patients to assess longer-term repercussions of
the rehabilitation program this was beyond the scope of
this study (after all over a longer time period of time
conditions may change and obscure any intervention's
effects by threatening the study's internal validity). The
fact that the number of men was unequal to that of
women may actually underestimate baseline anxiety and
depression scores, since women tend to have higher
levels of both, but such a choice would have eliminated
the representativeness of the sample (women with
COPD, despite a steady increase in number, still remain
fewer than men). An important problem in the study is
that a substantial number of patients have chosen to dis-
continue the rehabilitation program and a subsequent
study should examine whether psychological factors are
involved in patients attrition. Understanding the prob-
lem should not aim at excluding patients with COPD
from rehabilitation programs, but to create individual-
ized interventions both before and during rehabilitation.
Conclusion
Our study supports that pulmonary rehabilitation pro-
grams should be offered to all COPD patients regardless
of disease severity, since they all get improvements in
anxiety and depressive symptoms. Further research
would be useful to confirm these findings and to focus
on the possibilities of intervention and rehabilitation in
patients with mild COPD.
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